Vermillion Eyeing Return to Nasdaq, Launches OVA1 Ovarian Cancer Test with Quest Dx | GenomeWeb

This story originally ran on March 10 and has been updated to include additional information on Medicare's decision to cover OVA1.

Vermillion this week launched its OVA1 triage ovarian cancer test as part of its effort to return to commercial viability.

OVA1 is being made available through Quest Diagnostics, who is launching the test along with Vermillion. Medicare is also covering the test, Vermillion said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.